The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment

Haematologica

Volumn 89, Issue 9, 2004, Pages 1118-1123

  Giuliani, Nicola ^a   Colla, Simona ^a   Morandi, Francesca ^a   Rizzoli, Vittorio ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Interleukin 11; Interleukin 6; Microenvironment; Multiple myeloma; RANKL

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 11; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN; RANK PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW; BONE MARROW STROMAL CELL; CELL CONTACT; CELL INTERACTION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; ENDOTHELIUM CELL; GENE; HUMAN; HUMAN CELL; MICROENVIRONMENT; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOCLAST; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RANK GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; UPREGULATION; WESTERN BLOTTING;

BONE MARROW; CARRIER PROTEINS; CELL COMMUNICATION; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; INTERLEUKIN-11; INTERLEUKIN-6; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; OSTEOCLASTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RNA, MESSENGER; RNA, NEOPLASM; STROMAL CELLS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 4644343663     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003;4: 557-64.
2. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2:927-37.
3. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
4. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001;98: 11581-6.
5. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001; 98:3527-33.
6. Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P, et al. Receptor activator of nuclear factor-κ8 ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 2003;63:5438-45.
7. Okada T, Akikusa S, Okuno H, Kodaka M. Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. Clin Exp Metastasis 2003;20:639-46.
8. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, et al. Soluble receptor activator of nuclear factor {κ}B ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003;102:1064-9.
9. Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, Van Camp B, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003;63:287-9.
10. Uciyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993;82: 3712-20.
11. Hjertner O, Torgersen ML, Seidel C, Hjorth-Hansen H, Waage A, Borset M, et al. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood 1999;94:3883-8.
12. Lehr J-E, Pienta K-J. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst 1998;90:118-23.
13. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003;197: 1537-49.
14. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993;82: 3712-20.
15. Roux S, Meignin V, Quillard J, Meduri G, Guiochon-Mantel A, Fermand JP, et al. RANK (receptor activator of nuclear factor-κB) and RANKL expression in multiple myeloma. Br J Haematol 2002;117: 86-92.
16. Bu R, Borysenko CW, Li Y, Cao L, Sabokbar A, Blair HC. Expression and function of TNF-family proteins and receptors in human osteoblasts. Bone 2003;33:760-70.
17. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000;95:2630-6.
18. Manolagas SC. Role of cytokines in bone resorption. Bone 1995;17:63S-7S.
19. Astaldi GC, Janssen MC, Lansdorp PM, Zeijlemaker WP, Willems C. Human endothelial culture supernatant (HECS): evidence for a growth-promoting factor binding to hybridoma and myeloma cells. J Immunol 1981;126:1170-3.
20. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93:3064-73.
21. Kim HH, Shin HS, Kwak HJ, Ahn KY, Kim JH, Lee HJ, et al. RANKL regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. FASEB J 2003; 17:2163-5.